WHAT YOU NEED TO KNOW
- Wells Fargo upgraded BP to Overweight and raised its price target to $57, citing debt reduction progress and capital allocation flexibility.
- Exxon Mobil was downgraded to Equal Weight as Wells Fargo said relative valuation was converging in BP’s favor.
- Goldman Sachs upgraded Occidental to Buy, while Liquidia faced downgrades after its Delaware court loss.
- Citi launched Rocket Lab coverage with a Buy rating and a $105 target, indicating 51% upside.
Wall Street analysts delivered a broad round of rating changes across energy, biotechnology, utilities, insurance, aerospace and consumer companies. The calls compiled by The Fly included upgrades, downgrades and newly initiated coverage, with several significant price target revisions.
Wells Fargo upgraded BP to Overweight from Equal Weight and raised its price target to $57 from $48. The firm said commodity and trading conditions continue to pull forward BP’s $14B debt target while providing flexibility for capital allocation.
The same firm downgraded Exxon Mobil to Equal Weight from Overweight, assigning the oil major a $182 price target. Wells Fargo sees relative valuation converging in BP’s favor, supported by accelerated debt reduction and resource development.
Goldman Sachs upgraded Occidental to Buy from Neutral and increased its price target to $69 from $63. The firm cited a strong outlook for reducing debt and the potential for dividend growth.
Argus moved Regeneron to Buy from Hold and established an $850 price target. According to the firm, the recent pullback in Regeneron shares created an attractive point of entry for investors.
BTIG upgraded United Therapeutics to Buy from Neutral with a $728 price target. The firm said the company’s legal victory against Liquidia clears the way for growth to resume through 2027.
Wells Fargo also raised Consolidated Edison to Overweight from Equal Weight. Its price target increased to $118 from $108, with the utility viewed as a defensive source of diversification away from the broader artificial intelligence trade.
Liquidia faced downgrades following its Delaware court loss involving United Therapeutics’ '327 patent. Raymond James cut Liquidia to Outperform from Strong Buy and slashed its price target to $53 from $106, while BTIG separately lowered the company to Neutral from Buy.
Raymond James said the court decision removes PH-ILD from the Yutrepia/L606 model. The ruling also creates uncertainty involving labels, damages and possible market restrictions, according to the firm’s research note.
UBS downgraded Ormat Technologies to Neutral from Buy and reduced its price target to $100 from $157. The firm expects limited potential for earnings upside through 2028 and views Ormat’s valuation multiples as generally aligned with peers.
JPMorgan downgraded Ethos to Neutral from Overweight while maintaining its $37 price target, citing valuation. The bank also lowered Baldwin Group to Neutral from Overweight and raised its target to $32 from $30.
Baldwin Group agreed to be acquired by Sequence Holdings and Dell Family Office Management in a transaction that would take the company private at $32.50 per share. That agreement formed the backdrop to JPMorgan’s revised rating and target.
Among newly launched coverage, Citi began following Rocket Lab with a Buy rating and a $105 price target, representing 51% upside. The firm said Rocket Lab is among the few companies worldwide providing regular commercial access to orbit.
TD Cowen initiated coverage of Teva with a Buy rating and a $55 price target. The firm said Teva’s approved agents across neuropsychiatry and central nervous system indications support prospects for continued growth.
Needham started coverage of Freshpet with a Hold rating and no price target. The firm considers Freshpet a quality leader within the refrigerated dog food category, which Needham described as attractive.
JPMorgan initiated coverage of Spyre Therapeutics with an Overweight rating and a $110 price target. The firm believes Spyre owns multiple assets aimed at proven therapeutic targets that could improve efficacy for patients with IBD compared with the current standard of care.
Oppenheimer began covering Vita Coco with an Outperform rating and a $70 price target. The firm expects sales growth in the double digits over the next few years, supported by opportunities to increase U.S. household penetration and expand usage occasions.
The day’s calls created a clear split within major energy names. BP and Occidental received upgrades tied to debt reduction and capital prospects, while Exxon Mobil was downgraded as Wells Fargo judged the relative valuation balance to be moving toward BP.
Join the Discussion
COMMENTS POLICY: We have no tolerance for messages of violence, racism, vulgarity, obscenity or other such discourteous behavior. Thank you for contributing to a respectful and useful online dialogue.